

## Synthesis and Biological Evaluation of 23-Oxa-, 23-Thia- and 23-Oxa-24-oxo-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>

K. Allewaert, H. Van Baelen and R. Bouillon\*

Laboratorium voor Experimentele Geneeskunde en Endocrinologie, K.U. Leuven,  
Onderwijs en Navorsing Gasthuisberg, Herestraat, 49, B-3030 LEUVEN (Belgium)

Xu-yang Zhao, P. De Clercq, M. Vandewalle\*


University of Gent, Department of Organic Chemistry, Laboratory for Organic Synthesis,  
Krijgslaan, 281 (S.4), B-9000 GENT (Belgium)

(Received 15 January 1993)

**Abstract :** The synthesis includes the side-chain construction starting from the Inhoffen-Lythgoe diol and coupling with the A ring. Both 23-oxa- and 23-thia-analogues showed a decreased cell differentiating effect but even a more decreased calcemic effect compared with 1 $\alpha$ ,25-(OH)<sub>2</sub>D<sub>3</sub>.

### Introduction


The active form of vitamin D, 1 $\alpha$ ,25-(OH)<sub>2</sub>D<sub>3</sub>, regulates serum calcium homeostasis by promoting intestinal calcium transport and bone mineral turnover.<sup>1</sup> The hormone 1 $\alpha$ ,25-(OH)<sub>2</sub>D<sub>3</sub> has also an important effect on cell proliferation and cell differentiation.<sup>2</sup> In search of separating the hypercalcemic from the differentiating activity, new analogues have been synthesized with variations in the side chain, known to be a major discriminating part of the molecule.<sup>3</sup> Such interesting separation was found with 22-oxa-1 $\alpha$ ,25-(OH)<sub>2</sub>D<sub>3</sub> which was more active in suppressing proliferation and inducing differentiation of HL-60 cells whereas the calcemic effects are less than 1 % of 1 $\alpha$ ,25-(OH)<sub>2</sub>D<sub>3</sub>.<sup>4</sup> These results stimulated the synthesis of three analogues with a heteroatom at the 23-position, namely 23-oxa-1 $\alpha$ ,25-(OH)<sub>2</sub>D<sub>3</sub> (**1**)<sup>5,6</sup>, 23-thia-1 $\alpha$ ,25-(OH)<sub>2</sub>D<sub>3</sub> (**2**)<sup>7</sup> and 23-oxa-24-oxo-1 $\alpha$ ,25-(OH)<sub>2</sub>D<sub>3</sub> (**3**). The differentiation inducing activity on HL-60 cells of **1** and **2** has already been tested in vitro by Kubodera et al.<sup>7</sup> No remarkable differences were observed between these analogues which had circa 20 % activity of 1 $\alpha$ ,25-(OH)<sub>2</sub>D<sub>3</sub>.



### Synthesis

The analogue 23-oxa-1 $\alpha$ ,25-(OH)<sub>2</sub>D<sub>3</sub> (**1**) has already been described by a few research groups.<sup>5,6</sup> The approaches involve alkylation of the 22-hydroxyl function by 3-chloro-2-methyl-1-propene **9** or bromo t.butylacetate and subsequent formation of the 25-hydroxyl group; the starting material being either the Inhoffen-Lythgoe diol **4**<sup>5</sup> or a 1 $\alpha$ -hydroxy-isovitamin derivative.<sup>6</sup> In the case of the alkylation of **4** with **9**<sup>5</sup> a

low chemoselectivity was observed. This necessitated selective protection of the secondary hydroxyl group resulting in a 7-step sequence for the synthesis of ketone **7**. In search for a shorter sequence we decided to study the nucleophilic displacement on epoxide **5** which is less electrophilic than allylic chloride **9** and could thus show a higher selectivity. Several conditions were examined for this transformation; the only successful method involved powdered KOH in DMSO. This gave a clean reaction as only ether **6** was obtained next to starting material. Subsequent oxidation afforded keto-alcohol **7**. Ketone **7** was then coupled with the known A-ring phosphine oxide **14**,<sup>8</sup> after *in situ* protection of the 25-hydroxyl group as a TMS-ether. Deprotection using Amberlyst-15<sup>R</sup> led to analogue **1**.



(a) powdered KOH, DMSO, 30°C, 17.5 h; (b) PDC, CH<sub>2</sub>Cl<sub>2</sub>, rt, 3 h; (c) p-TsCl, pyridine, 0°C, 15 h; (d) DMSO, 50–60°C, 2 h and then aq. NaOH, 45–50°C, 2 h; (e) Hg(OAc)<sub>2</sub>, H<sub>2</sub>O/THF, 40–50°C, 2 h and then 3 M NaOH, NaBH<sub>4</sub>, rt, 96% (based on recovered **10**); (f) (CH<sub>3</sub>)<sub>2</sub>C(OH)COOH, K<sub>2</sub>CO<sub>3</sub>, DMSO, 35°C, 42 h; (g) (i) N-TMS-imidazole, THF, rt, 2 h, (ii) n-BuLi, THF, -78°C, 2 h and then rt, 0.5 h; (h) Amberlyst-15<sup>R</sup>, THF/MeOH, rt, 16 h; (i) (n-Bu)<sub>4</sub>NF, THF, rt, 11 h.

SCHEME 1

The 23-thia analogue **2** has already been described; the synthesis involves the nucleophilic substitution of the 22-mesylate in a provitamin skeleton with 1-mercapto-2-methyl-2-hydroxypropane.<sup>7</sup> We independently developed a synthesis starting from the known monotosylate **8** while avoiding the use of a mercaptan. We therefore developed a one-pot process taking advantage of the thiourea-method<sup>9</sup> for producing thiols from halides. Indeed, upon mixing **8**, **9** and thiourea in DMSO in the presence of NaOH, the desired sulfide **10** was produced in high yield. The oxymercuration-reductive demercuration of **10** led to the tertiary alcohol in 61% yield next to starting material (36%); the reaction did not reach completion due to complexation of the sulfur

atom and the mercuric ion. Finally, oxidation of the secondary hydroxyl group afforded ketone **11**, which was coupled with **14** as described for **7**.

The synthesis of the analogue **3** is straightforward and involves formation of the  $\alpha$ -hydroxy-butyrate **12** from tosylate **8**; subsequent oxidation to ketone **13** and coupling with **14**, as described for **7**, yielded the desired product **3**.

#### Biochemical evaluation

To evaluate the affinity of the analogues **1**, **2** and **3** to the vitamin D receptor, [<sup>3</sup>H]1 $\alpha$ ,25-(OH)<sub>2</sub>D<sub>3</sub> (specific activity 180 Ci/mmol Amersham, Buckinghamshire, United Kingdom) and increasing amounts of 1 $\alpha$ ,25-(OH)<sub>2</sub>D<sub>3</sub> or of **1**, **2** and **3** were incubated with the rat intestinal mucosa cytosol. The relative affinity of the analogues was calculated from their concentration needed to displace 50 % of [<sup>3</sup>H]1 $\alpha$ ,25-(OH)<sub>2</sub>D<sub>3</sub> (assigned 100 %). All three had a decreased receptor binding (Table I).

#### Biological evaluation

The cell differentiating effect of **1**, **2** and **3** was evaluated in human promyeloid leukemia cells (HL-60 cells) by the induction of superoxide production measured by 4-nitro-blue-tetrazolium (NBT) reduction.<sup>10</sup> Their relative potency was compared to that of 1 $\alpha$ ,25-(OH)<sub>2</sub>D<sub>3</sub> (Table 1).

The calcemic effects on vitamin D deficient chicks was evaluated by measuring serum calcium after 10 days of daily intramuscular injection of increasing amounts of analogues.<sup>11,12</sup> All three had reduced calcemic effects as their activity was less than 2 % of that of 1 $\alpha$ ,25-(OH)<sub>2</sub>D<sub>3</sub>. The cell differentiating effect of the 23-heteroatoms analogs was relatively higher than their calcemic effect. The dissociation of their effects was less than that of 22-oxa-1 $\alpha$ ,25-(OH)<sub>2</sub>D<sub>3</sub>.

TABLE 1. Biological activity of the analogues as assessed by their relative affinity for the intestinal mucosal vitamin D receptor and their capability to induce differentiation of human promyeloid leukemia cells (HL-60). The activities are compared with those of 1 $\alpha$ ,25-(OH)<sub>2</sub>D<sub>3</sub> (assigned a value of 100 %).

Analogue	Receptor binding	HL-60 cell differentiation
<b>1</b>	2	9
<b>2</b>	13	29
<b>3</b>	26	6

**Acknowledgements.** We thank the "NFWO" and the "Ministerie voor Wetenschapsbeleid" for financial support to the laboratory.

#### References

1. Bouillon, R.; Van Baelen, H. *Saudi Medical Journal* **1989**, *10*, 260.
2. Abe, E.; Miyaura, C.; Sakagami, H.; Takedo, M.; Konno, K.; Yamazaki, T.; Yoshiki, S.; Suda, T. *Proc. Natl. Acad. Sci. USA* **1981**, *78*, 4990.
3. For a review, see: Ikekawa, N. *Med. Res. Rev.* **1987**, *7*, 333. Also *Vitamin D Gene Regulation, Structure-Function Analysis and Clinical Application*. Ed. Norman, A.W.; Bouillon, R.; Thomasset, M.; Walter de Gruyter, Berlin, New York 1991.
4. Brown, A.J.; Ritter, C.R.; Finch, J.L.; Morrissey, J.; Martin, K.J.; Murayama, E.; Nishii, Y.; Slatopolsky, E. *J. Clin. Invest.* **1989**, *84*, 728.
5. Wilson, S.R.; Yasmin, A. *Proceedings of the Eighth Workshop on Vitamin D*, Paris, France, Norman, A.W.; Bouillon, R.; Thomasset, M. Eds., Walter de Gruyter, Berlin, New York, **1991**, p. 178. This method had previously been described for the synthesis of 23-oxa-25-hydroxy-vitamin D<sub>3</sub>, ref. Toh, H.T.; Okamura, W.H. *J. Org. Chem.* **1983**, *48*, 1414.

6. Neel, G.; Steinmayer, A. *Tetrahedron Lett.* **1991**, 32, 5073.
7. Kubodera, N.; Miyamoto, K.; Akiyama, M.; Matsumoto, M.; Mori, T. *Chem. Pharm. Bull.* **1991**, 39, 3221.
8. Baggiolini, E.G.; Zacobelli, J.A.; Hennessy, B.M.; Batcho, A.D.; Sereno, J.F.; Uskokovic, M.R. *J. Org. Chem.* **1986**, 51, 3098.
9. "A text-book of practical organic chemistry including qualitative organic analysis", A.Z. Vogel, Third Edition, **1967**, p. 497
10. Ostrem, V.K.; Tanaka, Y.; Prahl, J.; Deluca, H.F.; Ikekawa, N. *Proc. Natl. Acad. Sci. (USA)* **1987**, 84, 2610.
11. Bouillon, R.; Allewaert, K.; Van Leeuwen, J.P.T.M.; Tan, B.K.; Xiang, D.Z.; De Clercq, P.; Vandewalle, M.; Pols, H.A.P.; Bos, M.P.; Van Baelen, H.; Birkenhäger, J.C. *J. Biol. Chem.* **1992**, 267, 3044.
12. Bouillon, R.; Allewaert, K.; Xiang, D.Z.; Tan, B.K.; Van Baelen, H.; Bone, J. *Miner. Res.* **1991**, 6, 3044.